S100A8 as blood biomarker for the non-invasive diagnosis of Endometriosis
AssigneeRoche Diagnostics Operations, Inc.
InventorsAikaterini Georgopoulou, Martin Hund
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of S100A8 in a sample of the patient, and comparing the determined amount or concentration to a reference.
Claims25
A non-invasive method of assessing whether a patient has endometriosis or is at risk of developing endometriosis, comprising
- measuring the amount or concentration of S100 calcium binding protein A8 (S100A8) in a sample of the patient, wherein the sample is a body fluid selected from the group consisting of blood, serum, and plasma, and
- comparing the measured amount or concentration to a reference,
- wherein the patient has stage I endometriosis according to revised American Society for Reproductive Medicine (rASRM) staging or stage II endometriosis according to rASRM staging, and
- administering a therapy for endometriosis to the patient, wherein the therapy is selected from the group consisting of a drug-based therapy, a surgical therapy, and a hormonal therapy.
A non-invasive method of selecting a patient for drug-based therapy or surgical therapy (laparoscopy) of endometriosis, comprising
- measuring the amount or concentration of S100A8 in a sample of the patient, wherein the sample is a body fluid selected from the group consisting of blood, serum, and plasma, and
- comparing the measured amount or concentration to a reference,
- wherein the patient is suspected of having or has stage I endometriosis according to rASRM staging or stage II endometriosis according to rASRM staging, and
- administering the drug-based therapy or performing the surgical therapy on the patient selected for therapy.
A non-invasive method of monitoring a patient suffering from endometriosis or being treated for endometriosis, comprising
- measuring the amount or concentration of S100A8 in a sample of the patient, wherein the sample is a body fluid selected from the group consisting of blood, serum, and plasma, and
- comparing the measured amount or concentration to a reference,
- wherein the patient is suspected of having or has stage I endometriosis according to rASRM staging or stage II endometriosis according to rASRM staging, and
- administering a therapy for endometriosis to the patient based on the monitoring, wherein the therapy is selected from the group consisting of a drug-based therapy, a surgical therapy, and a hormonal therapy.
A method of detecting S100A8 in a sample from a patient, the method comprising:
- obtaining the sample from the patient, wherein the sample is a body fluid selected from the group consisting of blood, serum, and plasma, and
- detecting whether S100A8 is present in the sample by contacting the sample with a binding agent and detecting the binding between S100A8 and the binding agent,
- wherein the binding agent is an antibody that specifically binds to S100A8, and wherein the patient is suspected of having or has stage I endometriosis according to rASRM staging or stage II endometriosis according to rASRM staging.
A method for measuring the amount of S100A8 in a sample from a patient, the method comprising:
- obtaining the sample from the patient, wherein the sample is a body fluid selected from the group consisting of blood, serum, and plasma,
- measuring the amount of S100A8 in the sample of the patient, and
- contacting the sample, or a portion thereof, with an agent which specifically binds S100A8, wherein the agent is an antibody and wherein the patient is suspected of having or has stage I endometriosis according to rASRM staging or stage II endometriosis according to rASRM staging.
A non-invasive method of assessing whether a patient has endometriosis or is at risk of developing endometriosis, wherein the patient is suspected of having or has stage I endometriosis according to rASRM staging or stage II endometriosis according to rASRM staging, comprising
- measuring the amount or concentration of S100A8 in a sample of the patient, wherein the measuring comprises incubating the sample of the patient with one or more antibodies specifically binding to S100A8 thereby generating a complex between the one or more antibodies and S100A8, and quantifying the complex thereby quantifying the amount of S100A8 in the sample of the patient,
- comparing the measured amount or concentration to a reference,
- assessing whether the patient has endometriosis or is at risk of developing endometriosis,
- wherein the sample is a body fluid selected from the group consisting of blood, serum, and plasma, and
- administering a therapy for endometriosis to the patient, wherein the therapy is selected from the group consisting of a drug-based therapy, a surgical therapy, and a hormonal therapy.
A non-invasive method of assessing whether a patient has endometriosis or is at risk of developing endometriosis, comprising
- measuring the amount or concentration of S100 calcium binding protein A8 (S100A8) in a sample of the patient, wherein the sample is a body fluid selected from the group consisting of blood, serum, and plasma, and
- comparing the measured amount or concentration to a reference,
- wherein the patient has stage I endometriosis according to revised American Society for Reproductive Medicine (rASRM) staging or stage II endometriosis according to rASRM staging, and
- administering a therapy for endometriosis to the patient, wherein the therapy is selected from the group consisting of a drug-based therapy, a surgical therapy, and a hormonal therapy.
Dependencies are inferred from the claim text.